With deep sorrow, Research to Prevent Blindness (RPB) announces the passing of John I. Bloomberg, who served on the RPB Board of Trustees from 2007 to 2017.
The latest grant cycle supports eye research related to a variety of diseases and conditions.
RPB-supported vision researchers at Washington University School of Medicine in St. Louis have contributed key data to a new study that identifies a natural compound that slows typical signs of aging in mice.
Twenty-two emerging vision scientists conducted Capitol Hill visits with NAEVR and RPB to champion federal funding for critical vision research.
A common pathway involved in photoreceptor death has been identified in retinitis pigmentosa, advanced dry age-related macular degeneration and other retinal diseases, with early evidence of a possible halt to vision loss related to pathway treatment.
The National Academies of Sciences, Engineering, and Medicine issues nine concrete recommendations for improving eye and vision health and increasing health equity.
Researchers publish critical findings from Zika mouse model, raising the possibility of new avenues of transmission, as well as confirming the virus’ ability to induce cell death in eyes.
Research initiative to address urgent needs in understanding and treating low vision.
Total of 36 grants go to medical schools and individual scientists across the U.S.
A new approach to removing congenital cataracts in infants allows remaining stem cells to regrow functional lenses.
The number of people with visual impairment (VI) and blindness is increasing in the U.S. and around the world.
At the ARVO Inaugural Press Conference, three RPB-funded scientists pushing the boundaries of imaging, early detection, regeneration.
Study reveals a way to inhibit excessive growth of lymphatic vessels which contribute to organ transplant rejection, cancer metastasis, lymphatic obstruction, diabetes and hypertension.
Protein analysis can make diagnoses more accurate and treatments better targeted to individual patients.
Adults whose eyes are slow to adjust to the dark have a greater risk of developing age-related macular degeneration.
Some patients taking high doses of a cholesterol-lowering medication had complete resolution of lipid deposits in the dry form of age-related macular degeneration (AMD).
Findings raise the possibility of treating blinding eye diseases using a patient's own corrected cells as replacement tissue
A finding that opens the door to improving retinal prosthetic devices, targeting treatments to restore damaged retinal circuits, and improving early detection of retinal diseases.
RPB-supported commentary on approaches to using the anti-VEGF therapy.
RPB is recognized for the leadership role it has played in many advances in the field of ophthalmology.
RPB-supported researchers have made a significant discovery that might lead to the delay or prevention of the most common cause of blindness in the elderly.
RPB-supported researchers have partially reversed cataracts in dogs using eye drops and injections of a naturally occurring steroid in the human body.
View can help researchers understand how the brain’s connectivity is disrupted in mental and neurological conditions such as schizophrenia, depression, anxiety, autism and in vision-related conditions.
|General Info||Research Scientists & Grantees||Eye Care Specialists||Donors & Partners|